Halozyme Therapeutics Inc (HALO)

16.42
NASDAQ : Health Care
Prev Close 16.42
Day Low/High 0.00 / 0.00
52 Wk Low/High 8.18 / 17.55
Avg Volume 1.17M
Exchange NASDAQ
Shares Outstanding 141.92M
Market Cap 2.37B
EPS -0.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

There Are Good Opportunities in Stock Picking

There Are Good Opportunities in Stock Picking

The indices may need a rest, but stock-pickers have an edge.

Halozyme Jumps on Immuno-Oncology Deal with Bristol-Myers

Halozyme Jumps on Immuno-Oncology Deal with Bristol-Myers

Pharma giant aims to develop cancer drug delivery technology. Halozyme shares are up more than 16% in pre-market trading.

Bristol-Myers Squibb And Halozyme Enter Global Collaboration And License Agreement For ENHANZE Technology

Bristol-Myers Squibb And Halozyme Enter Global Collaboration And License Agreement For ENHANZE Technology

Bristol-Myers Squibb Company (NYSE:BMY) and Halozyme Therapeutics, Inc.

HaloSource Secures $2.2 Million In Funding To Accelerate Drinking Water Market Presence

HaloSource Secures $2.2 Million In Funding To Accelerate Drinking Water Market Presence

Company also announces agreement with online marketing giant to drive Chinese sales

Initiation Of Clinical Trial Collaboration Evaluating Halozyme's PEGPH20 In Combination With Anti-PDL1 Immunotherapy

Initiation Of Clinical Trial Collaboration Evaluating Halozyme's PEGPH20 In Combination With Anti-PDL1 Immunotherapy

First Study Evaluating Combination of PEGPH20 and atezolizumab in Pancreatic Cancer

Halozyme Phase 2 Data In Advanced Pancreas Cancer Presented At European Society For Medical Oncology Symposium

--Findings in Two Oral Presentations and Three Poster Presentations Continue to Support Ongoing HALO-301 Phase 3 Study--

Short Interest Drops 12.6% For HALO

The most recent short interest data has been released for the 05/31/2017 settlement date, which shows a 3,135,029 share decrease in total short interest for Halozyme Therapeutics Inc , to 21,693,822, a decrease of 12.63% since 05/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Halozyme Phase 2 Data In Advanced Pancreas Cancer Featured In An Oral Presentation At ASCO

-Presentation Includes Newly Reported Objective Response Rate and Patient Baseline Characteristics from HALO-202-

Biotech Movers: Lion Biotechnologies, XBiotech, Halozyme

Biotech Movers: Lion Biotechnologies, XBiotech, Halozyme

Lion Biotechnologies, XBiotech and Halozyme Therapeutics were among the biotech movers in premarket trading on Friday.

Halozyme Phase 2 Data In Advanced Pancreas Cancer To Be Featured In An Oral Presentation At ASCO

-HALO-202 Study Met Primary, Key Secondary Endpoints and Demonstrated a Statistically Significant Improvement in Progression-Free Survival (PFS) in Patients with High Levels of Hyaluronan-

If You Don't Buy These 5 Stocks Before Their Looming Breakout, It's Your Loss

If You Don't Buy These 5 Stocks Before Their Looming Breakout, It's Your Loss

Here's how to potentially rake in some fat profits off a number of hot breakout setups.

Biotech Premarket Movers: Halozyme, Omeros, Aralez

Biotech Premarket Movers: Halozyme, Omeros, Aralez

Halozyme Therapeutics, Omeros and Aralez Pharmaceuticals were among the biotech stock movers in premarket trading on Thursday.

Slowly but Surely, Post-Fed Euphoria Dissipates

Slowly but Surely, Post-Fed Euphoria Dissipates

The market response to the Fed was quite extreme, although there really wasn't any major development.

There Should Be More Selling

There's certainly enough weakness in the market.

TheStreet Quant Rating: D (Sell)